Abstracts Archive - Page 2338 of 2425 - ACR Meeting Abstracts

Abstract Number: 1270 • 2012 ACR/ARHP Annual Meeting
Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration
Iris Navarro-Millan¹, Shuo Yang², Scott L. DuVall³, Lang Chen⁴, John Baddley⁵, Grant W. Cannon⁶, Elizabeth S. Delzell⁷, Jie Zhang⁸, Monika M. Safford⁹, Nivedita M. Patkar¹⁰, Ted R. Mikuls¹¹, Jasvinder A. Singh¹² and Jeffrey R. Curtis⁸, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹²Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Rheumatoid arthritis (RA) increases the risk for coronary heart disease and ischemic events like myocardial infarction (MI). The association between traditional cardiovascular risk factors in…
Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
HC Leffers¹, Mikkel Østergaard¹, Bente Glintborg², Niels Steen Krogh³, Ulrik Tarp⁴, Tove Lorenzen⁵, Annette Hansen⁶, Michael Sejer Hansen⁷, Lene Dreyer², Martin S. Jakobsen² and Merete Lund Hetland⁸, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Gildhøj Privathospital, Copenhagen, Denmark, ⁸DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…
Abstract Number: 1272 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Incomplete Secondary Responders to TNF-Alpha Safely Achieve Efficacy by Switching to Certolizumab Pegol in a 24-Week Study: A Phase IV, Randomized Multicenter, Double-Blind, Twelve-Week Study Followed by a 12 -Week Open-Label Phase
M. Schiff¹, Ronald Goldblum² and John RP Tesser³, ¹University of Colorado, Denver, CO, ²CPC, Inc, Carlsbad, CA, ³AZ Arthritis Rheum Assoc, Paradise Valley, AZ
Background/Purpose: Certolizumab pegol (CZP), an inhibitor of TNF-alpha, has demonstrated rapid and sustained efficacy in RA patients. Switching from one anti-TNF therapy to another has…
Abstract Number: 1273 • 2012 ACR/ARHP Annual Meeting
Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?
Noortje van Herwaarden¹, Aatke van der Maas¹, Tim L. Jansen², Ellen Dutmer³, Andre Hartkamp⁴, Piet L.C.M. van Riel⁵, Wietske Kievit⁵, Bart J.F. van den Bemt⁶ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud UMC, Nijmegen, Netherlands, ³Rheumatology, Gelderse Vallei Hospital, Ede, Netherlands, ⁴Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, ⁵Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: The optimal retreatment strategy for rituximab is not clear1. Different strategies are being used in clinical practice, including: on demand retreatment when disease activity…
Abstract Number: 1274 • 2012 ACR/ARHP Annual Meeting
Relationship Between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a 12 Week Efficacy Study of a Modified (Delayed-Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Frank Buttgereit¹, John R. Kirwan², Kenneth G. Saag³, Reike Alten⁴, Amy Grahn⁵, Patricia Rice⁶ and Maarten Boers⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ³Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁴Charité Univ Medicine, Berlin, Germany, ⁵Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁶Statistics, CliniRx Research, Naperville, IL, ⁷Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: RA patients typically present with pain and morning stiffness (MS). MS is predictive of both functional disability and escalated RA care, but the best…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 1236 • 2012 ACR/ARHP Annual Meeting
Important Prognostic Factor in Rheumatoid Arthritis Patients with Interstitial Lung Disease Is Not Usual Interstitial Pneumonia Pattern but Interstitial Lung Disease Extent On Chest High-Resolution Computed Tomography
Hwajeong Lee¹, Jung-Yoon Choe², Seong-Kyu Kim², Sung Hoon Park², Ji Hun Kim², Dae Sung Hyun³, Kyung Jae Jung⁴ and Jisuk Bae⁵, ¹Catholic University of Daegu School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ³Division of Pulmonology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, South Korea, ⁴Radiology, Catholic University of Daegu School of Medicine, South Korea, ⁵Department of Preventive Medicine, Catholic University of Daegu School of Medicine, South Korea
Background/Purpose: Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis (RA), and an important cause of morbidity and mortality in RA patients.…
Abstract Number: 1237 • 2012 ACR/ARHP Annual Meeting
Baseline Evaluation of Insulin Resistance in Patients with early Non-Treated Rheumatoid Arthritis
Sara Manrique-Arija¹, María América López-Lasanta², Pilar Espiño- Lorenzo², Pedro Valdivielso³, José Rioja³, Inmaculada Ureña¹, Francisco Gabriel Jimenez- Núñez¹, Carmen M. Romero-Barco¹, Veronica Rodríguez-García¹, Laura Nieves², Mari Carmen Ordoñez-Cañizares², Laura Cano², Maria Victoria Irigoyen² and Antonio Fernández-Nebro⁴, ¹Rheumatology, Hospital Carlos Haya. University of Malaga, Malaga, Spain, ²Hospital Carlos Haya. University of Malaga, Malaga, Spain, ³Department of Medicine. University of Malaga, Malaga, Spain, ⁴Rheumatology, Hospital Carlos Haya. University of Malaga. IBIMA, Malaga, Spain
Background/Purpose: High levels of inflammatory cytokines are associated with insulin resistance syndrome in long-standing AR. The aim was to analyze insulin resistance (IR), adipokines, inflammatory…
Abstract Number: 1238 • 2012 ACR/ARHP Annual Meeting
Effects of Stress On Clinical Presentation of Patients with Early Rheumatoid Arthritis
Yun A. Kim¹, Jane E. Salmon², Juan Xiong³, Boulos Haraoui⁴, Carol A. Hitchon⁵, Edward Keystone⁶, Janet E. Pope⁷, Diane Tin⁸, J. Carter Thorne⁹, Gilles Boire¹⁰, Vivian P. Bykerk² and CATCH¹¹, ¹Hospital for Special Surgery (and Kwangju Christian Hospital, Gwangju, Korea), New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹¹Toronto
Background/Purpose: Stress is related to pathogenesis and progression of inflammatory autoimmune disorders. The aim of this study is to evaluate the role of patient (pt)…
Abstract Number: 1239 • 2012 ACR/ARHP Annual Meeting
Soluble Glycoprotein VI: A Novel Risk Marker for Thrombosis in Patients with Inflammatory Arthritis
Leann Bell¹, Anne M. Madigan², Paul A. MacMullan², Eimear Dunne³, Dermot Kenny³ and Geraldine M. McCarthy¹, ¹Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Patients with inflammatory arthritis (IA) such as rheumatoid arthritis (RA) are at high risk of cardiovascular mortality. Increased platelet reactivity is a risk marker…
Abstract Number: 1240 • 2012 ACR/ARHP Annual Meeting
Serum Anti-Müllerian Hormone Can Be Used to Determine Ovarian Reserve in Women with Rheumatoid Arthritis
Jenny Brouwer¹, Johanna M.W. Hazes², Joop S.E. Laven³, Izaäk Schipper³ and Radboud J.E.M. Dolhain⁴, ¹Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Planning of pregnancy is important in women with rheumatoid arthritis (RA). It is preferred to start a pregnancy after adjustment of medication and when…
Abstract Number: 1241 • 2012 ACR/ARHP Annual Meeting
Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients
Lisa L. Schroeder¹, Xiaoqin Tang², Mary Chester M. Wasko³ and Androniki Bili⁴, ¹Rheumatology, Geisinger Health System, Danville, PA, ²Biostatistics, Geisinger Center for Health Research, Danville, PA, ³West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ⁴Rheumatology, Geisinger Medical Center, Danville, PA
Glucocorticoid use is associated with increase in HDL in Rheumatoid Arthritis PatientsBackground/Purpose: Atherogenic lipid profiles are common in active RA, with most common being decreased…
Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Mike Nurmohamed¹, Yanjun Bao², James Signorovitch³, Parvez M. Mulani⁴ and Daniel Furst⁵, ¹VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, ²AbbVie, North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
Abstract Number: 1243 • 2012 ACR/ARHP Annual Meeting
Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms
Hitomi Kobayashi¹, Isamu Yokoe², Hiroshi Sato¹ and Yasuyuki Kobayashi³, ¹Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ²Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of congestive heart failure, possibly via shared mechanisms of inflammation. This study was undertaken to…
Abstract Number: 1244 • 2012 ACR/ARHP Annual Meeting
Group Cycling in Rheumatoid Arthritis: Positive Effects On Aerobic Capacity and Blood Pressure
Lars Ångström¹, Kristina Hörnberg¹ and Solveig Wållberg Jonsson², ¹Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå Sweden, Dept of Rheumatology, Umeå, Sweden, ²Department of Public Health and Clinical Medicine, Dept of Rheumatology, Umeå, Sweden
Background/Purpose: Cardiovascular disease (CVD) is increased in rheumatoid arthritis (RA) (1). Strong evidence shows that exercise reduces the CVD risk in the general population (2).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].